Related Experiment Video
Updated: Jul 7, 2026
11:49
Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
Published on: April 3, 2026
Lymphadenectomy for isolated lymph node metastasis from extremity soft-tissue sarcomas
Waddah B Al-Refaie1, Robert H I Andtbacka, Joe Ensor
1Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77203-1402, USA.
Cancer
|February 29, 2008
Summary
Aggressive therapy, including lymphadenectomy, for extremity soft-tissue sarcomas (ESTS) with lymph node (LN) metastasis shows promising survival rates. These outcomes suggest a potential need to re-evaluate the current staging system for ESTS.
Area of Science:
- Oncology
- Surgical Oncology
- Cancer Research
Background:
- Extremity soft-tissue sarcomas (ESTS) with lymph node (LN) metastasis (stage IV) previously showed similar prognoses to high-risk ESTS without metastasis (stage III).
- Aggressive treatment, including lymphadenectomy, for ESTS with LN metastasis was evaluated.
Purpose of the Study:
- To determine the outcomes of patients with ESTS and LN metastasis who underwent aggressive therapy.
- To compare survival rates with established historical outcomes for American Joint Commission on Cancer (AJCC) stages III and IV ESTS.
Main Methods:
- Retrospective analysis of 35 patients with nodal metastasis from ESTS treated between 1981 and 2003.
- Data collected included demographics, primary tumor pathology, timing of LN metastasis, and multimodality treatment.
- Survival analysis was performed and compared to historical data.
Main Results:
- Epithelioid sarcomas and malignant fibrous histiocytomas were the most common primary types.
- 57% of patients presented with synchronous nodal metastasis.
- 5-year survival rates were 52% for synchronous and 66% for metachronous nodal metastasis after aggressive treatment.
Conclusions:
- Aggressive treatment, including lymphadenectomy, for isolated regional LN metastasis in ESTS may lead to prolonged survival.
- Survival outcomes approximate stage III disease more closely than stage IV.
- Findings support reconsideration of the current AJCC staging system for ESTS.
